A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to very severe chronic obstructive pulmonary disease (COPD) wiht a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. (RESOLUTE) (NCT04053634)
RESOLUTE
This trial is No longer recruiting
Registration number NCT04053634
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principle investigator
Associate Professor Eli Dabscheck
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.